甲磺酸达拉非尼

Description

dabrafenib mesylate · CAS 1195768-06-9 · C23H20F3N5O2S2. UNII QGP4HA4G1B. Boiling Point: 653.7; LogP: 2.9; Dissociation Constants: -1.5.

Identification

CAS Registry Number	1195768-06-9
PubChem CID	44462760
Molecular formula	C23H20F3N5O2S2
IUPAC name	N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
UNII (FDA)	QGP4HA4G1B

Computed Descriptors

Molecular Weight	519.6
XLogP3	4.8
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	6
Exact Mass	519.10105173
Monoisotopic Mass	519.10105173
Topological Polar Surface Area	147
Heavy Atom Count	35
Formal Charge	0

Physical & Chemical Properties

Boiling Point	653.7
LogP	2.9
Dissociation Constants	-1.5

Physical description & handling notes

• very slightly soluble at pH 1

GHS Hazard Classification

Reported hazard statements	H361 (22.2%), H373 (88.9%), H400 (100%), H410 (11.1%), H411 (88.9%)

Documented Uses

• Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase and is used alone or in combination with trametinib in the treatment of advanced malignant melanoma. Dabrafenib therapy is associated with transient elevations in serum aminotransferase during therapy, but has not been linked to instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors;
• Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of dabrafenib.
• Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of dabrafenib.
• Do not take with or immediately after a high-fat meal. Dabrafenib's bioavailability is reduced when taken with a high-fat meal.
• Take on an empty stomach. Take dabrafenib at least one hour before or two hours after a meal.

Synonyms

Dabrafenib; 1195765-45-7; GSK2118436A; GSK2118436; GSK-2118436; GSK-2118436A; QGP4HA4G1B; CHEBI:75045; DTXSID20152499; N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-(3-(5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3-THIAZOL-4-YL)-2-FLUOROPHENYL)-2,6-DIFLUOROBENZENESULFONAMIDE; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; dabrafenibum; RefChem:58040; DTXCID8074990; BRAF Inhibitor GSK2118436

Frequently Asked Questions

What are the CAS number and molecular formula of dabrafenib mesylate?

CAS 1195768-06-9; molecular formula C23H20F3N5O2S2; molecular weight — g/mol.

What other names is dabrafenib mesylate known by?

Dabrafenib, 1195765-45-7, GSK2118436A, GSK2118436, GSK-2118436, GSK-2118436A.

Is dabrafenib mesylate classified as hazardous?

Hazard statements reported: H361, H373, H400, H410, H411.

What are the key physical properties of dabrafenib mesylate?

Boiling Point: 653.7; LogP: 2.9; Dissociation Constants: -1.5.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.